Publications 2002

 

Flandre Ph, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Pialoux G, Aboulker JP, Brun-Vézinet F. Final analysis of the Trilège induction-maintenance trial: results at 18 months. AIDS 2002, 16 : 561-568.Lien PubMed

Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. The Lancet 2002, 359 : 733-740.Lien PubMed

Flandre P, Durier C, Descamps D, Launay O, Joly V. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: Statistical analysis and potential biases. J Acquir Immune Defic Syndr 2002, 30 : 59-64.Lien PubMed

Flandre P, Peytavin G, Meiffrédy V, Saidi Y, Descamps D, Delagnes M, Brun-Vezinet F, Raffi R. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antiviral Therapy 2002, 7 : 113-121. Lien PubMed

Joly V, Flandre P, Meiffrédy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P for the Novavir Study Group. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (Novavir Trial). Antimicrob Agents Chemother 2002, 46 : 1906-1913. Lien PubMed

Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Patrick Yéni P. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1. Clin Infect Dis 2002, 35 : 1096-1105. Lien PubMed

Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL, for the International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomised trial. JAMA 2002, 288 : 189-198.Lien PubMed

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F on behalf of the NOVAVIR (ANRS 073) Study Group. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. JAIDS 2002, 31 : 464-471. Lien PubMed

Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L and Sullivan JL for the Pediatric AIDS Clinical Trials Group Protocol 316 Team. Development of resistance mutations in women on standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal HIV-1 transmission: a substudy of Pediatric AIDS Clinical Trials Group protocol 316. JFNDIS 2002;186:181-188. Lien PubMed

Saman M, Kruy LS, Glaziou P, Rekacewicz C, Leng C, Delfraissy JF. Feasibility of antenatal and late HIV testing in pregnant women, in Phnom Penh Cambodia: preliminary results of the PERIKAM/ANRS1205 study. AIDS 2002;16:950-951. Lien PubMed

Joly V, Flandre P, Meiffrédy V, Leturque N, Harel M, Aboulker JP, Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.Lien PubMed